The patient-derived cell lines were resistant to lorlatinib and sensitized by mTOR inhibition and and treatment exposure, may result in the outgrowth of more aggressive tumor cells and force the acquisition of EMT features

The patient-derived cell lines were resistant to lorlatinib and sensitized by mTOR inhibition and and treatment exposure, may result in the outgrowth of more aggressive tumor cells and force the acquisition of EMT features. In summary, the mechanisms of resistance